Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Higher-risk Myelodysplastic Syndromes: early-phase trial registry
3 of 3 indexed Higher-risk Myelodysplastic Syndromes trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 3 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Higher-risk Myelodysplastic Syndromes: 3 US clinical trials tracked, 3 recruiting.
Higher-risk Myelodysplastic Syndromes is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Remix Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition higher-risk-myelodysplastic-syndromes
OPEN 3 | RECR 100% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Higher-risk Myelodysplastic Syndromes lists 3 open slots (100% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Higher-risk Myelodysplastic Syndromes on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Higher-risk Myelodysplastic Syndromes is recruiting above its size-band peers.
3 of 3 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Study of REM-422 in Patients With AML or Higher Risk MDS
Remix Therapeutics
NCT06297941
A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
Akeso
NCT06196203
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
AstraZeneca
NCT07155226
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Higher-risk Myelodysplastic Syndromes records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Higher-risk Myelodysplastic Syndromes trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Higher-risk Myelodysplastic Syndromes page
3 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Higher-risk Myelodysplastic Syndromes trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Remix Therapeutics sponsors the most Higher-risk Myelodysplastic Syndromes trials on record, review their full trial history before evaluating a specific study. See Remix Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Higher-risk Myelodysplastic Syndromes condition card totals 3 registered trials; most-linked intervention REM-422; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.